Atrial fibrillation and the pharmacological treatment: the role of propafenone

被引:1
|
作者
Sestito, A. [1 ]
Molina, E. [2 ]
机构
[1] Univ Cattolica Sacro Cuore, Sch Med, Dept Cardiol, I-00168 Rome, Italy
[2] Univ Parma, Sch Med, Dept Pharmacol, I-43100 Parma, Italy
关键词
Atrial fibrillation (AF); Acute onset AF; Prevention of AF recurrences; Antiarrhythmic drugs; Propafenone; SINUS RHYTHM; SUSTAINED-RELEASE; ORAL PROPAFENONE; MANAGEMENT; CONVERSION; EFFICACY; PREVENTION; THERAPY; TRIAL; RISK;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Atrial fibrillation is the most frequent cardiac rhythm disturbance, with prevalence increasing with age. This disease is a major risk factor for ischaemic stroke. The costs resulting from atrial fibrillation are really impressive. Pharmacological agents are the first line therapy for the management of atrial fibrillation. Antiarrhythmic drugs are used to terminate arrhythmias, as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. Among antiarrhythmic agents, drugs that inhibit early sodium current (as propafenone) are proven effective in atrial fibrillation. In this review, the most relevant data on propafenone are provided. Discussion: The development of a sustained-release formulation of propafenone allowed to reduce the wide fluctuations in plasma levels observed with the immediate release preparation, improving compliance and adherence to therapy, by simplifying the dosing regimen from 3 to 2 daily doses. Propafenone resulted an effective measure as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. In several clinical studies, strong increases of arrhythmia-free periods as well as marked increases in time to recurrence of symptomatic atrial fibrillation, such as paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation were observed. In particular, well-designed clinical studies demonstrated in large patient populations the efficacy of propafenone at several doses. At the suggested doses propafenone is usually well tolerated. Conclusion: The risk of increased occurrence of regular supraventricular arrhythmia or paroxysmal supraventricular tachycardia has been overestimated for propafenone, because this adverse event was seen in all treatment groups, including placebo, with the same (and low) frequency.
引用
收藏
页码:242 / 253
页数:12
相关论文
共 50 条
  • [21] Sotalol and propafenone have similar efficacy and tolerability for the treatment of patients with atrial fibrillation: The Canadian Trial of Atrial Fibrillation experience
    Thibault, B
    Roy, D
    Talajic, M
    Dubuc, M
    Newman, D
    Couturier, A
    CIRCULATION, 1999, 100 (18) : 502 - 502
  • [22] Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter
    Chiladakis, JA
    Kalogeropoulos, A
    Patsouras, N
    Manolis, AS
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (04) : 859 - 863
  • [23] Invasive versus pharmacological treatment in patients with atrial fibrillation
    Pytkowski, M
    Sterlinski, MS
    Kraska, A
    Kowalik, I
    Jankowska, A
    Kurowski, A
    Przybylski, A
    Szwed, H
    EUROPEAN HEART JOURNAL, 2001, 22 : 328 - 328
  • [24] Pharmacological treatment of atrial fibrillation: What does it take?
    Grunnet, Morten
    HEART RHYTHM, 2011, 8 (12) : 1940 - 1941
  • [25] Comparison of efficacy of pharmacological cardioversion with antazoline and propafenone versus electrical cardioversion in atrial fibrillation during cryoablation
    Klocek, Konrad
    Tworek, Michal
    Klimek, Katarzyna
    Zabochnicki, Mateusz
    Mazur, Marta
    Milewski, Krzysztof
    Kazmierczak, Pawel
    Janas, Adam
    POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2024, 20 (01): : 103 - 108
  • [26] Pharmacological Treatment of Atrial Fibrillation in Patients with Heart Failure
    Shiga, Tsuyoshi
    JOURNAL OF CARDIAC FAILURE, 2014, 20 (10) : S140 - S140
  • [27] Atrial fibrillation: from pharmacological treatment to electrical therapy
    Cristoni, L.
    Tampieri, A.
    Mucci, F.
    Iannone, P.
    Venturi, A.
    Cavazza, M.
    Lenzi, T.
    EMERGENCY CARE JOURNAL, 2010, 6 (04) : 8 - 9
  • [28] Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity
    Iwasa, A
    Okumura, K
    Tabuchi, T
    Tsuchiya, T
    Tsunoda, R
    Matsunaga, T
    Tayama, S
    Yasue, H
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 356 (01) : 31 - 40
  • [29] ATRIAL-FLUTTER IN PATIENTS TREATED FOR ATRIAL-FIBRILLATION WITH PROPAFENONE
    MURDOCK, CJ
    KYLES, AE
    YEUNGLAIWAH, JA
    QI, AH
    VORDERBRUGGE, S
    KERR, CR
    AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (07): : 755 - 757
  • [30] PROPAFENONE FOR SUPPRESSION OF REFRACTORY SYMPTOMATIC ATRIAL-FIBRILLATION
    ANTMAN, EM
    BEAMER, AD
    CANTILLON, C
    MCGOWAN, N
    FRIEDMAN, PL
    CIRCULATION, 1987, 76 (04) : 68 - 68